Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

Cancer

Volumn 117, Issue 20, 2011, Pages 4617-4622

  Welin, Staffan ^a   Sorbye, Halfdan ^b   Sebjornsen, Sigrunn ^b   Knappskog, Stian ^b,c   Busch, Christian ^b   Öberg, Kjell ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

Author keywords

chemotherapy; neuroendocrine cancer; PDEC; second line and temozolomide

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOCRINE TUMOR; FEMALE; GENE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; MALE; O6 METHYL GUANINE DNA METHYLTRANSFERASE GENE; OVERALL SURVIVAL; POORLY DIFFERENTIATED ENDOCRINE CARCINOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NEUROENDOCRINE; CISPLATIN; DACARBAZINE; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 79960027478     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26124     Document Type: Article

References (21)

1. Galanis E, Frytak S, Lloyd RV,. Extrapulmonary small cell carcinoma. Cancer. 1997; 79: 1729-1736. (Pubitemid 27176355)
2. Lee SS, Lee JL, Ryu MH, et al. Extrapulmonary small cell carcinoma: single center experience with 61 patients. Acta Oncol. 2007; 46: 846-851. (Pubitemid 47123777)
3. Solcia E KG, Sobin LH,. Histological Typing of Endocrine Tumours. New York: Springer; 2000.
4. Brenner B, Tang LH, Klimstra DS, Kelsen DP,. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol. 2004; 22: 2730-2739. (Pubitemid 41103762)
5. Kang H, O'Connell JB, Leonardi MJ, Maggard MA, McGory ML, Ko CY,. Rare tumors of the colon and rectum: a national review. Int J Colorectal Dis. 2007; 22: 183-189. (Pubitemid 44964021)
6. Ahlman H, Nilsson O, McNicol AM, et al. Poorly-differentiated endocrine carcinomas of midgut and hindgut origin. Neuroendocrinology. 2008; 87: 40-46. (Pubitemid 350308293)
7. Nilsson O, Van Cutsem E, Delle Fave G, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology. 2006; 84: 212-215. (Pubitemid 46361055)
8. Moertel CG, Kvols LK, O'Connell MJ, Rubin J,. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227-232.
9. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999; 81: 1351-1355.
10. Hainsworth JD, Spigel DR, Litchy S, Greco FA,. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006; 24: 3548-3554. (Pubitemid 46630525)
11. Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res. 2007; 13: 2986-2991. (Pubitemid 46849574)
12. Kulke MH, Stuart K, Earle CC, et al. A phase II study of temozolomide and bevacizumab in patients with advanced neuroendocrine tumors [abstract]. J Clin Oncol. 2006; 24 (18S). ASCO Annual Meeting Proceedings (Post-Meeting Edition). Abstract 4044.
13. Isacoff WH, Moss RA, Pecora AL, Fine RL,. Temozolomide/capecitabine therapy for metastatic neuroendocrine tumors of the pancreas. A retrospective review [abstract]. J Clin Oncol. 2006; 24 (18S). ASCO Annual Meeting Proceedings (Post-Meeting Edition). Abstract 14023.
14. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117: 268-275.
15. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003. (Pubitemid 40349502)
16. Iwasa S, Morizane C, Okusaka T, et al. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas. Jpn J Clin Oncol. 2010; 40: 313-318.
17. Kulke MH, Wu B, Ryan DP, et al. A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci. 2006; 51: 1033-1038. (Pubitemid 44127047)
18. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001; 92: 1101-1107. (Pubitemid 32861657)
19. Binderup T, Knigge U, Loft A, et al. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med. 2010; 51: 704-712.
20. Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009; 15: 338-345.
21. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26: 2124-2130.